Delcath Systems, Inc. ( (DCTH) ) has released its Q1 earnings. Here is a breakdown of the information Delcath Systems, Inc. presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Delcath Systems, Inc. is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers through its proprietary products, HEPZATO KIT™ and CHEMOSAT®, which are designed to deliver high-dose chemotherapy to the liver while minimizing systemic exposure and side effects.
In the first quarter of 2025, Delcath Systems reported significant financial growth, with total revenue reaching $19.8 million, a substantial increase from $3.1 million in the same period the previous year. The company also achieved a net income of $1.1 million, marking a turnaround from a net loss of $11.1 million in the first quarter of 2024.
Key financial highlights include a gross margin improvement to 86% from 71% and a positive adjusted EBITDA of $7.6 million, compared to a loss of $7.3 million in the prior year. The company also expanded its operational footprint by activating new treatment centers and received FDA clearance for a phase 2 clinical trial of HEPZATO in liver-dominant metastatic breast cancer.
Delcath’s strategic advancements are underscored by the exercise of Series F warrants, which contributed $16.2 million in funding. The company’s cash and investments totaled $58.9 million as of March 31, 2025, with no debt, positioning it well for future growth and expansion.
Looking ahead, Delcath Systems remains focused on expanding the clinical adoption of its HEPZATO KIT and exploring additional indications, supported by ongoing dialogue with oncologists and interventional radiologists. The company is poised to continue its growth trajectory as it leverages its innovative treatment solutions for liver cancer patients.